Pharmafile Logo

Novel Oncology Therapies Require Innovative Methods in Oncology Modeling

May 16, 2023 |  

Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.

Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.

Health technology assessment (HTA) agencies have long required evidence of long-term survival and lifetime estimates of quality of life before they will approve new treatments. Health economics and outcomes research analysts have relied on standard parametric models to extrapolate overall survival rates from clinical trial data to estimate quality of life.

This traditional approach identifies the statistical models that best fit the available data and then uses these models to predict outcomes over the lifetime. It worked well for traditional cancer treatments, including chemotherapy. However, many new oncology drugs have a different mechanism of action—including the possibility of delayed and prolonged response to treatment and, potentially, cure—which may not be accurately represented by these traditional models.

Applying standard models to novel oncology therapies may lead to inaccurate estimates of survival and/or quality-of-life benefits, which could cause HTA agencies to reject beneficial treatments. For patients to access potentially lifesaving medications, analysts need to use more sophisticated modeling methods that can accommodate the potentially complex hazard patterns associated with these treatments.

Choosing an oncology modeling method

Newer methods and techniques may better capture the potential value of innovative oncology treatments.

The appropriate modeling method can provide the foundation for an accurate assessment of the benefits associated with novel oncology therapies—a crucial step in gaining regulatory approval and getting treatment to those who need it. However, determining which model to use can be challenging.

In January 2020, the National Institute for Health and Care Excellence, Decision Support Unit issued Technical Support Document 21 (TSD 21), a guide to flexible methods for survival analysis. This document suggested some innovative modeling approaches, including cure models, mixture modeling, piecewise models and landmark approaches, and encouraged careful consideration of the tradeoff between short-term fit versus long-term assumptions. These newer methods aim to more accurately estimate the value of new drugs in terms of cost, life years and quality of life.

TSD 21, however, did not specify when—or under which circumstances—specific models should be used.

At present, guidance is limited as to when flexible models should be considered, and which might be most appropriate for a particular data set. An advisory board of seven international experts with in-depth knowledge of survival analysis and health technology assessment collaborated over the summer of 2021 to produce an algorithm that can be used to inform selection of flexible survival oncology models.

The algorithm, which consists of eight steps and four questions, was published in Value in Health journal in August 2022. It provides a systematic, evidence-based approach to justify the selection of extrapolation models for immunotherapeutic cancer medications, and, if followed, should reduce the risk of selecting inappropriate models that may underestimate the benefit of novel treatments.

Oncology modeling continues to play a vital role in determining (and demonstrating) the value of new cancer treatments, but traditional methods aren’t a good fit for new drugs that have prolonged responses. Flexible extrapolation models offer a better estimate of the value of new drugs. They offer cost-effective analyses of cancer immunotherapies and other innovative oncology therapies.

At OPEN Health, we use advanced survival modeling techniques as needed to demonstrate value. Our multidisciplinary teams have deep knowledge of oncology modeling and routinely help pharmaceutical companies navigate health technology assessments and joint clinical assessments.

Learn more about OPEN Health: https://www.openhealthgroup.com/

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

Pharmerit rebrands to OPEN Health

OPEN Health is moving to one brand to create a world-class integrated services model

Rare Disease Day 2021

To mark Rare Disease Day 2021 on Sunday 28 February, OPEN Health will be intentionally quiet on all LinkedIn channels from 26 February to 1 March in order not to...

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health

If the heart of the medical affairs industry is ultimately improving patient outcomes, internal training is the regenerative liver. Med affairs professionals need to regularly update their scientific knowledge and...

What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health

How fantastic is it to see that the National Organisation for Rare Disorders (NORD) has followed up on a survey undertaken in the late 80’s to pressure test progress and identify...

OPEN Health Group Appoints New Leadership

OPEN Health Group today announced that Rob Barker has been appointed Chief Executive Officer. Rob succeeds outgoing CEO and Co-Founder, David Rowley, who is stepping down after 10 years. A...

OPEN VIE and Pharmerit Bring the Best of Both Worlds to Virtual ISPOR Europe 2020

Join OPEN VIE and Pharmerit – an OPEN Health Company at the ISPOR European Virtual Conference from 16-19 November 2020 to see how we are shaping the healthcare industry with...

OPEN Health brings the Best of Both Worlds to MAPS EMEA 2020

Strategy and execution, data and insight, experience and innovation…what do you look for in an agency partner?OPEN Health is a family of expert practices working in partnership to drive positive...

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward

The COVID-19 pandemic has permanently changed how medical education in the healthcare industry is conducted. Over the last few months, all conferences, medical education and field force deliverables have either...

How Far Do You Want To Go?

Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…